Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Bio-Techne Corporation (TECH:NASDAQ), powered by AI.
Bio-Techne Corporation is currently trading at $54.00. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Bio-Techne Corporation on Alpha Lenz.
Bio-Techne Corporation's P/E ratio is 115.9.
“Bio-Techne Corporation trades at a P/E of 115.9 (premium valuation) with modest ROE of 3.7%.”
Ask for details →Bio-Techne Corporation is a leading developer and manufacturer of high-quality biological products and solutions for the research and clinical diagnostic markets. The company specializes in providing an extensive range of biotechnological tools that support the advancement of life sciences. Key offerings include proteins, antibodies, assay kits, and laboratory services critical for scientific research and drug development. Bio-Techne operates across diverse sectors such as biotechnology, pharmaceuticals, academic research, and healthcare, supplying innovative solutions that facilitate groundbreaking research and therapeutic discoveries. Its products are essential in advancing modern biology and medicine, contributing to significant developments in areas like cancer research, immunology, and cell biology. Bio-Techne’s commitment to innovation and quality makes it a pivotal player in the biotechnology industry, elevating scientific discovery and fostering advancements in personalized medicine and diagnostics. With a strong global presence, Bio-Techne continues to impact the global life sciences landscape profoundly, upholding a legacy of excellence and reliability in the biotechnological sector.
“Bio-Techne Corporation trades at a P/E of 115.9 (premium valuation) with modest ROE of 3.7%.”
Ask for details →Bio-Techne Corporation (ticker: TECH) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 3,100 employees. Market cap is $8.5B.
The current price is $54 with a P/E ratio of 115.89x and P/B of 4.43x.
ROE is 3.68% and operating margin is 19.91%. Annual revenue is $1.2B.